Abstract
Background
Propranolol, a non-selective blocker of the β-adrenoceptor (AR), is a first-line treatment for infantile hemangioma (IH). Mast cells have been implicated in the pathophysiology of propranolol-treated hemangioma. However, the function of mast cells remains unclear.
Methods
HMC-1s (Human mast cell line) having been treated with propranolol for 24 h were centrifuged, washed with PBS twice, and maintained in cell culture medium for another 24 h. The supernatants with propranolol which were named as propranolol-treated HMC-1s supernatants were obtained. The expression of cytokines and mediators was examined among HMC-1s dealt with propranolol. HemECs (hemangioma endothelial cells) were co-cultured with propranolol-treated HMC-1s supernatants, and their proliferation and apoptosis were investigated. The autophagic-related protein was examined in HemECs using immunoblot.
Results
In propranolol-treated HMC-1s, the expressions of ADRB1 (β1-AR) and ADRB2 (β2-AR) were reduced by 70% and 60%, respectively, and that of cytokines and mediators were reduced. The proliferation was decreased, but apoptosis and autophagy were induced in HemECs treated with propranolol-treated HMC-1s supernatants. However, propranolol can work well in shRNA-ADRB1 or shRNA-ADRB2 transfected HMC-1s.
Conclusions
Propranolol inhibit the proliferation of HemECs and promote their apoptosis and autophagy through acting on both β1 and β2 adrenoceptor in mast cell.
Impact
-
Treated with propranolol, β1, and β2 adrenoceptor on human mast cell expression was reduced significantly.
-
After hemangioma endothelial cell treated with the supernatants from propranolol-treated human mast cell, its proliferation was decreased, but apoptosis and autophagy were significantly induced.
-
Propranolol can work well in shRNA-ADRB1 or shRNA-ADRB2 transfected HMC-1s. Mast cells may have a role in the action of propranolol in infantile hemangioma through both β1 and β2 adrenoceptors to inhibit the angiogenic capacity of hemangioma endothelial cells.
Similar content being viewed by others
Introduction
Infantile hemangioma (IH) is a benign vascular tumor that commonly occurs in early infancy, with a prevalence of ~5–10% in infants.1 A significant minority of IH cases in the proliferating phase require medication to prevent complications such as disfigurement, functional impairment, and ulceration.2 In 2008, Léauté-Labrèze et al. reported that propranolol, a non-selective β-adrenoceptor (AR) blocker, inhibited the growth of IH. Because of its safety and relatively few side effects, propranolol has replaced corticosteroids as the first-line therapy for problematic IH.3
In recent years, the cellular and molecular mechanisms, by which propranolol exerts its effects, have been widely investigated. Ji et al. demonstrated that propranolol inhibited the proliferation and induces apoptosis of endothelial cells within hemangiomas, which was mediated by the suppression of vascular endothelial growth factor A (VEGF-A) expression.4 IH tissues treated with propranolol were found to be richly infiltrated by mast cells.5 Furthermore, β-AR were reported to be highly expressed on mast cells in propranolol-treated IH.6 However, the function of mast cells in propranolol-treated IH remains unclear.
Mast cells have been implicated in the pathophysiology of hemangioma. It was found that several mast cell mediators such as VEGF-A, basic fibroblast growth factor (bFGF), histamine, heparin, interleukin-8 (IL-8), and tumor necrosis factor-α (TNF-α) may serve as endothelial cell mitogen.7 It is also reported that VEGF-A and bFGF are major mediators in mast cell-mediated angiogenesis.7
In our previous study, we found that following propranolol treatment, mast cell activation can reduce the proliferation and increase the apoptosis of human umbilical vein blood endothelial cells (HUVEC, Supplementary Data). In this study, we analyzed whether human mast cells treated with propranolol could affect the proliferation, apoptosis, or autophagy of hemangioma endothelial cells (HemECs).
Methods
HMC-1s culture
HMC-1s were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). HMC-1s were cultured in high glucose Dulbecco’s modified Eagle’s medium (DMEM, ThermoFisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY), 0.05 mM beta-mercaptoethanol, 2mM l-glutamine, 0.1 mM non-essential amino acids, 10 ng/mL interleukin-3 (IL-3), and 10 ng/mL human stem cell factor (SCF).
β1-AR and β1-AR transduction assays
Lentiviral particles containing β1-AR (ADRB1) shRNA vectors, β2-AR (ADRB2) shRNA vectors, or non-silencing control vector DNA (Thermo Scientific-Open Biosystems) were generated by reverse transfection of these constructs, together with Trans-Lentiviral package mix, into HEK293T cells using Arrest-In/Express-In transfection reagent. Approximately 106 TU/mL was used to infect HMC-1 cells in the presence of polybrene (10 μg/mL) and a stable culture was generated by growing these cells in the presence of 1 μg/mL puromycin, the lowest concentration observed to kill 63% ADRB1- and 55% ADRB2-transduced-HMC-1 cells. All reagents for these transduction assays were purchased from Thermo Scientific. The shRNA sequences were as follows: forward, 5′-CACCGGAAAGTTTGGGAAGGGATGGCGAACCATCCCTTCCCAAACTTTCC-3′ and reverse, 5′ AAAAGGAAAGTTTGGGAAGGGATGGTTCGCCATCCCTTCCCAAACTTTCC-3′ for ADRB1; forward, 5′-CACCGCATCGTCATGTCTCTCATCGCGAACGATGAGAGACATGACGATGC-3′ and reverse, 5′-AAAAGCATCGTCATGTCTCTCATCGTTCGCGATGAGAGACATGACGATGC-3′ for ADRB2.
Propranolol treatment
A stock solution of propranolol (Merck, Darmstadt, Germany) was prepared at 100 mM in Dimethyl sulfoxide (DMSO) and stored at 4 °C. For all the treatments, the final concentration of DMSO in the medium was 0.1%. SingleQuot was excluded in the experiments because this agent affected cell survival. Before each treatment, cells were plated on the indicated plates and cultured in standard media as previously mentioned. The HMC-1s supernatants were available. Twenty-four hours later, the medium was replaced with EBM-2 supplemented with FBS and the indicated concentrations of propranolol. Propranolol-treated HMC-1s supernatants were obtained. HMC-1s treated with 0.1% DMSO was set as the control group.
Isolation and culture of HemECs
This study was approved by the Ethics Committee of Children’s Hospital of Fudan University. Tissue samples were collected from two subjects suffering from infantile hemangioma (the proliferative phase) treated by surgical resection without any medication. Informed consent was obtained from the subjects’ parents. The clinical diagnosis of vascular neoplasms was confirmed by the Department of Pathology at Children’s Hospital of Fudan University through staining for GLUT-1, a marker specific for hemangioma tissue. The hemangioma samples were minced into small pieces using a scalpel and treated with a human tumor cell dissociation kit (Miltenyi Biotec, Cologne, bergesch gladbach, Germany). All cells were filtered through a 40-μm strainer to obtain a single-cell suspension. HemECs were isolated using human CD31 MicroBead Kit (Miltenyi Biotec, Cologne, bergesch gladbach, Germany).8 The HemECs were fluorescently stained with CD31-FITC and analyzed using FACS CantoII flow cytometer (FACS CantoII, BD, Franklin Lakes, NJ). These HemECs were plated on gelatin-coated 60-mm plates in Endothelial Basal Medium (EBM-2; Lonza, Walkersville, MD) supplemented with 20% heat-inactivated fetal bovine serum (FBS; Gibco, Grand Island, NY), SingleQuot (Lonza), penicillin (100 units/mL; Gibco), and streptomycin (100 μg/mL; Gibco, Grand Island, NY). The cells were grown in a humidified atmosphere containing 5% CO2 at 37 °C.
HemECs proliferation and apoptosis analysis
The HemECs dealt with DMSO-treated HMC-1s supernatants were designated as the control group while that with propranolol-treated HMC-1 supernatants were referred as experimental group. HemECs were seeded at 4 × 103 cells/well in the 96-well plates. Cell proliferation was assessed by CCK-8 proliferation assay (Dojindo, Shanghai, China). After cells were cultured for 1, 2, 3, or 4 d, 10 µL CCK-8 solution was added to each well of a 96-well plate. After the plate was incubated at 37 °C for another 4 h, optical density (OD) at 450 nm was measured against a solution blank in a microplate reader (MultiSkan FC, ThermoFisher, Foster City). Cell apoptosis was assayed using a commercially available Annexin V-FITC apoptosis detection kit I (BD Biosciences, San Jose, CA) and flow cytometry. Briefly, the cells were trypsinized, harvested, washed, and resuspended with 100 mL 1× binding buffer at a final concentration of 1 × 106 cells/mL. Then the cells were stained with 5 μL Annexin V/FITC followed by 1 μL PI and incubated in the dark for 15 min at room temperature. The apoptotic cells were analyzed by FACS CantoII flow cytometer (FACS CantoII, BD, Franklin Lakes, NJ).
Real-time quantitative polymerase chain reaction analysis
The expression of the cytokines and mediators VEGF-A, bFGF, matrix metalloproteinase (MMP)2, MMP9, and tryptase were evaluated by PCR in HMC-1 cells and transduced-HMC-1 cells. Total RNA was extracted using TriZol reagent (ThermoFisher Scientific, Waltham, MA). Isolated RNA was reverse-transcribed using Reverse Transcriptase M-MLV (Takara, Dalian, China) and then amplified using Takara SYBR Premix Ex Taq (Takara, Dalian, China) according to the manufacturer’s instructions. Primers for qPCR assays were from Sangon Biotech Company (Shanghai, China) and their sequences are shown in Table 1. The qPCR assays were performed in triplicate on an ABI 7500 Real-Time PCR instrument (Applied Biosystems, Foster City), according to the manufacturer’s protocols. All assays had a single amplification peak on the melting temperature curve with PCR efficiencies >80% and coefficients of variance of less than 15%, in triplicate reactions. Relative expression levels were calculated using the comparative Ct method.
Enzyme-linked immunosorbent assay
The concentrations of VEGF-A, bFGF, MMP2, MMP9, and tryptase in HMC-1 cells and transduced-HMC-1 cells after propranolol therapy were measured with enzyme-linked immunosorbent assay kits, according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN).
Western blot assay
HemECs treated with propranolol-treated HMC-1 supernatants were collected at 48 h and lysed in M-PER mammalian protein extraction lysis buffer (Thermo Scientific, Hudson, NH) for 30 min. Then total protein was extracted from the collected cells with RIPA lysis buffer (Zhong-Shan JinQiao, Beijing, China). Protein concentrations were evaluated by BCA protein assay kits (CoWin Biotechnology, Beijing, China). Equal amounts of total proteins (40 μg) were subjected to 10% SDS-PAGE and subsequently transferred onto polyvinylidene difluoride membranes (PVDF; Millipore, Boston, MA). Then PVDF membranes were blocked with 5% milk for 1 h and incubated with primary antibodies against ATG5, ATG7, p62, LC-3I, and LC-3II (1:1000; Cell Signaling Technology, Danvers, MA) and GAPDH (1:1000; Cell Signaling Technology) followed by overnight incubation at 4 °C. The membranes were further incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz Biotechnology) and the protein bands were visualized by chemiluminescence using ECL reagent (Millipore Corp., Billerica, MA). IPP7.0 software (Media Cybernetics, Silver Springs, MD) was used for quantitative analysis, with GAPDH as the internal control. Relative protein expression was calculated from the gray value target band and the gray value internal control.
Statistical analysis
Data are expressed as mean ± standard deviation. An independent sample t-test was applied to identify significant differences between the two groups. One-way ANOVA followed by the S-N-K method was used to determine significant differences among multiple groups. All data analyses were performed using SPSS11.0 statistical software and differences were considered significant at P < 0.05.
Results
Propranolol decreased the expression of ADRB1, ADRB2, VEGF-A, bFGF, MMP2, MMP9, and tryptase in HMC-1s
The mRNA expression levels of ADRB1 and ADRB2 were decreased significantly to the lowest level in HMC-1s treated with 10 μM propranolol (Fig. 1a). When HMC-1s were treated with 10 μM propranolol 24 h, the mRNA and protein expression of VEGF-A, bFGF, MMP2, MMP9, and tryptase were both significantly decreased (Fig. 1b, c).
Propranolol-treated HMC-1s supernatants inhibited the proliferation and induced the apoptosis of HemECs
After incubation with propranolol-treated HMC-1s supernatants for 24 and 48 h, respectively, the proliferations (cell counts) of HemECs were significantly less than those from the control group in HemECs dealt with 0.1% DMSO-treated HMC-1s supernatants (P < 0.01) (Fig. 2a). After incubation with propranolol-treated HMC-1s supernatants 48 h, the percentage of Annexin V positive and Annexin V/PI positive HemECs was two times as the control group in which HemECs was dealt with 0.1% DMSO-treated HMC-1 supernatants (34.76% vs. 18.65%; P < 0.01) (Fig. 2b–e).
Propranolol-treated HMC-1 supernatants induced autophagy in HemECs
Western blot assay was performed to determine the levels of autophagy-related proteins ATG5, ATG7, P62, and autophagy markers LC-3I and LC-3II of HemECs at 48 h. Compared with the control group, propranolol-treated HMC-1s supernatants increased the expression of LC-3II/I, ATG5, ATG7, and P62 in HemECs (Fig. 3).
Expression of cytokines and mediators in propranolol-treated HMC-1s transfected with shRNA-ADRB1 and shRNA-ADRB2
In order to explore which subtype β-AR on mast cells was acted upon by propranolol, we use β-AR transduction assay. The mRNA expression of ADRB1 was decreased by 67% in HMC-1s transfected with shRNA-ADRB1 while that of ADRB2 was decreased by 58% in HMC-1s transfected with shRNA-ADRB2 compared with HMC-1s transfected with negative control (NC) at 24 h (Fig. 4a). The mRNA and protein expression of cytokines and mediators VEGF-A, bFGF2, MMP2, MMP9, and TPSAB1 (tryptase) were slightly decreased (Fig. 4b, c) in HMC-1s transfected with shRNA-ADRB1 or shRNA-ADRB2 for 48 h. When the shRNA-ADRB1 or shRNA-ADRB2 transfected HMC-1s were treated with propranolol, the expression of cytokines and mediators was decreased sharply.
Discussion
Propranolol, a non-selective adrenergic antagonist, is a first-line treatment for IH.3 The precise mechanism by which propranolol induce accelerated involution of IH remains to be fully elucidated. Potential explanations for the therapeutic effects of propranolol in IH include vasoconstriction, inhibition angiogenesis, induction capillary endothelial cell apoptosis, and increased pericyte contractility.9,10,11,12,13 The effects of propranolol on several important cell types in IH, including hemangioma stem cells, hemangioma endothelial cells, hemangioma perivascular cells were reported in recent studies.9,10,11,12,13 Mast cell-infiltrating propranolol-treated IH lesions were reported previously.6,14,15 In our study, we found that propranolol might affect HemEC proliferation, apoptosis, and autophagy by acting on β- adrenoceptors and modulating the secretion of cytokines and mediator from HMC-1s.
The pathogenesis of IH has not been fully elucidated. It was postulated that IH was formed by the proliferation of immature endothelial cells stimulated by angiogenic factors.16,17,18 Cytokines and growth factors induce the formation of a capillary network by endothelial cells.16,17 The most extensively studied cytokines involved in the growth of IH are VEGF-A, bFGF, MMP2, and MMP9.18,19,20,21 VEGF-A is involved in vascular proliferation and permeability,19,21,22 and is produced by various cell types including endothelial cells, macrophages, platelets, and tumor cells. VEGF-A stimulates the migration of vascular endothelial cells, the proliferation and formation of new vessels, and the inhibition of apoptosis.22 MMPs are secreted by mast cells and tumor cells and are involved in angiogenesis by degrading components of the extracellular matrix, allowing for the formation of new vessels.23 Increased levels of MMP2 and MMP9 have been observed in tissue, blood, and urine samples from children in the proliferative phase of IH.23 There is evidence that MMP2 and MMP9 are regulated by β-adrenoceptors.24
Mast cells had been shown to abundantly infiltrate hemangioma tissues.25,26,27 There is evidence that several mast cell mediators, such as VEGF-A, bFGF, histamine, heparin, IL-8, TNF-α, platelet derived growth factor (PDGF), and hepatocyte growth factor (HGF) may serve as endothelial cell mitogens.7 VEGF-A and bFGF are potent angiogenic factors in the proliferating phase but not in the latter phases of hemangioma.20,28 An in vivo study confirmed that VEGF-A and bFGF are major mediators in mast cell-mediated angiogenesis.20,29 In addition, tryptase, MMPs, IL-3, IL-4, IL-8, and other cytokines produced by mast cells might contribute to the angiogenic process through the degradation of the extracellular matrix.30,31
Mast cells expressed high β1-AR and β2-AR,6 indicating that mast cells be the possible targets of propranolol. However, the function of mast cells in propranolol-treated IH remains unclear. In our study, VEGF-A, bFGF, MMP2, MMP9, and tryptase expression in mast cells treated with propranolol was significantly reduced at the mRNA and protein level. After propranolol-treated HMC-1 supernatants were co-cultured with HemECs for 24 h, it was found that the proliferation of HemECs was decreased, but their apoptosis and autophagy were significantly increased. To our knowledge, our study was the first to explore the potential mechanism on the act of mast cells in propranolol-treated IH.
Furthermore, we explored which subtype β-AR on mast cells was acted upon by propranolol through the β-AR transduction assay. In this study, the expression of β1-AR and β2-AR was decreased by 62% and 56% by ADRB1 and ADRB2 knockdown in HMC-1 cells, respectively. The expression levels of VEGF-A, bFGF, MMP2, MMP9, and tryptase in propranolol-treated HMC-1s transfected with shRNA-ADRB1 or shRNA-ADRB2 was decreased slightly at the mRNA and protein level much lower than that in propranolol-treated HMC-1s. These findings demonstrated that propranolol can simultaneously act on the β1 and β2 adrenoceptors of mast cells.
In the previous study, we found that after propranolol treatment, mast cell can reduce the proliferation and increase the apoptosis of HUVEC (Supplementary Data). However, it was a pity that this study did not include other endothelial cells or other cells of hemangioma tissue.
In conclusion, this study demonstrated that propranolol acted on the mast cell β1 and β2 adrenoceptors to inhibit the expression of VEGF-A, bFGF, MMP2, MMP9, and tryptase of mast cells in vitro. Thus, propranolol-treated HMC-1 supernatants can inhibit the proliferation and promote the apoptosis and autophagy of infantile angiomatous endothelial cells. Propranolol may have a role on mast cell in IH, which could provide a new theoretical basis for mast cells as target cells for the treatment of infantile hemangioma.
References
Kilcline, C. & Frieden, I. J. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr. Dermatol. 25, 168–173 (2008).
Holmes, W. J. M., Mishra, A., Gorst, C. & Liew, S. H. Propranolol as first-line treatment for rapidly proliferating Infantile Haemangiomas. J. Plast. Reconstr. Aesthet. Surg. 64, 445–451 (2011).
Leaute-Labreze, C. et al. Propranolol for severe hemangiomas of infancy. N. Engl. J. Med. 358, 2649–2651 (2008).
Ji, Y. et al. Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. J. Pediatr. Surg. 47, 2216–2223 (2012).
Steel, R. & Day, D. Increased apoptosis and secretion of tryptase by mast cells in infantile haemangioma treated with propranolol. Pathology 46, 496–500 (2014).
Prey, S. et al. Mast cells as possible targets of propranolol therapy: an immunohistological study of beta-adrenoceptors in infantile haemangiomas. Histopathology 65, 436–439 (2014).
Norrby, K. Mast cells and angiogenesis. Apmis 110, 355–371 (2002).
Norgall, S. et al. Elevated expression of VEGF-AR-3 in lymphatic endothelial cells from lymphangioms. BMC Cancer 21, 105 (2007).
Lee, D. et al. Propranolol targets the contractility of infantile haemangioma-derived pericytes. Br. J. Dermatol. 171, 1129–1137 (2014).
Chim, H. et al. Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. Ann. Surg. 256, 146–156 (2012).
Edwards, A. K. et al. NOTCH3 regulates stem-to-mural cell differentiation in infantile hemangioma. JCI Insight 2, e93764 (2017).
Tu, J. B. et al. Induction of apoptosis in infantile hemangioma endothelial cells by propranolol. Exp. Ther. Med. 6, 574–578 (2013).
Zou, H. X., Jia, J., Zhang, W. F., Sun, Z. J. & Zhao, Y. F. Propranolol inhibits endothelial progenitor cell homing: a possible treatment mechanism of infantile hemangioma. Cardiovasc. Pathol. 22, 203–210 (2013).
Itinteang, T. et al. Mast cells ininfantile haemangioma possess a primitive myeloid phenotype. J. Clin. Pathol. 66, 597–600 (2013).
Tan, E. M. et al. Characterisation of subpopulations of myeloid cells in infantile haemangioma. J. Clin. Pathol. 68, 571–574 (2015).
Itinteang, T., Withers, A. H., Davis, P. F. & Tan, S. T. Biology of infantile hemangioma. Front. Surg. 1, 38 (2014).
Greenberger, S. & Bischoff, J. Pathogenesis of infantile haemangioma. Brit. J. Dermatol 169, 12–19 (2013).
Liekens, S., De Clercq, E. & Neyts, J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61, 253–270 (2001).
Greenberger, S., Boscolo, E., Adini, I., Mulliken, J. B. & Bischoff, J. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N. Engl. J. Med. 362, 1005–1013 (2010).
Park, M. et al. Serum cytokine profiles in infants with infantile hemagimomas on oral propranolol treatment: VEGF-A and bFGF, potential biomarkers predicting clinical outcomes. Pediatr. Res. 88, 749–755 (2020).
Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52–67 (2010).
Kleinman, M. E. et al. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler. Thromb. Vasc. Biol. 27, 2664–2670 (2007).
Zhong, S., Yang, G. H., Xia, C., Zhang, D. L. & Shan, S. G. Expression of matrix metalloproteinase and its tissue inhibitor in haemangioma. J. Huazhong. U. Sci. Med 29, 614–619 (2009).
Ji, Y., Chen, S., Xu, C., Li, L. & Xiang, B. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br. J. Dermatol. 172, 24–32 (2015).
Tan, S. T., Wallis, R. A., He, Y. & Davis, P. F. Mast cells and hemangioma. Plast. Reconstr. Surg. 113, 999–1011 (2004).
Qu, Z. H. et al. Mast-cells are a major source of basic fibroblast growth-factor in chronic inflammation and cutaneous hemangioma. Am. J. Pathol. 147, 564–573 (1995).
Takahashi, K. et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J. Clin. Invest. 93, 2357–2364 (1994).
Chang, J. et al. Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Plast. Reconstr. Surg. 103, 1–9 (1999).
Yin, R. R., Hao, D. & Chen, P. Expression and correlation of MMP-9, VEGF-A, and p16 in infantile hemangioma. Eur. Rev. Med. Pharmacol. Sci. 22, 4806–4811 (2018).
Marler, J. J. et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics 116, 38–45 (2005).
Rotter, A. et al. Evaluation of plasma and urinary levels of vascular endothelial growth factor and matrix metalloproteinase-9 in patients with infantile hemangioma. Int. J. Dermatol. 6, https://doi.org/10.1111/ijd.15640 (2021).
Acknowledgements
We thank Bo Fang, Ph.D. for technical assistance. We also thank H. Nikki March, Ph.D., for editing the English text of a draft of this manuscript.
Author information
Authors and Affiliations
Contributions
Y.Y. and L.W. designed the study. H.Z., Y.Y., and L.D. performed the research and wrote the paper. H.Z. and L.D. analyzed the data. W.S., C.D., and J.L. collected clinical samples and data. W.L. assisted in clinical data collection. L.H. and W.G. assisted in subject enrollment. C.X., G.D., and K.L. offered technical assistance and helped to design the study. L.W. financially supported and revised the paper.
Corresponding author
Ethics declarations
Funding
This work was supported by a Natural Science Foundation of Shanghai grant (No. 16ZR1403900).
Competing interests
The authors declare no competing interests.
Ethical approval
The study was approved by the Ethics Committee of Children’s Hospital of Fudan University. Written informed parental consent was obtained at enrollment.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Ye, Y., Zhong, H., Dou, L. et al. Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell. Pediatr Res 92, 424–429 (2022). https://doi.org/10.1038/s41390-021-01683-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41390-021-01683-4
This article is cited by
-
Recent updates in laryngeal hemangioma management: a scoping review
European Archives of Oto-Rhino-Laryngology (2024)